N30 Pharma, Inc.: Series B $10M

Posted in I - Series B, Q - 2Q10, R - ROCKY MOUNTAIN, X - Asthma, X - COPD, X - IBD, XX - CO

N30 Pharma (Boulder, CO) a preclinical-stage biopharmaceutical company focused on small molecules inhibting GSNOR for the potential treatment of asthma, COPD, inflammatory bowel disease and heart failure, closed a $10M Series B financing. Participants include Deerfield Management, Tiger Management, Bridger Capital and Swift Current Partners.

Apr

2010

GlobeImmune, Inc.: Series E $17.5M

Posted in I - Series E, Q - 1Q10, R - ROCKY MOUNTAIN, X - Hepatitis C, X - Oncology, X - Vaccines, XX - CO

GlobeImmune (Lousiville, CO) a clinical-stage biopharmaceutical company developing a therapeutic vaccine platform focused on pancreatic cancer and hepatitis C, Closed a $17.5M Series E financing. Participants include Generali Financial Holding, BSI, Celgene, Wexford Capital, Mellon Family Investment Company, Eminent Venture Capital, Boston Life Science Venture, WRF Capital, Partners Healthcare, Yasuda, Genentech, Biogen Idec, CIDC, PAC-LINK [...]

Sep

2009

Medivance, Inc.: Series E $8.1M

Posted in I - Series E, Q - 3Q09, R - SOUTH EAST, X - Device (Temp Mgmt.), XX - CO

Medivance (Louisville, KY) a commercial-stage device company focused on non-invasive core temperature management, closed a $8.1M Series E financing. Participants include Quellos Private Capital, MDY Healthcare, Cross Atlantic Partners, Skyline Ventures, Camden Partners, Partisan Management Group, Nikko Synergy Ventures, Kimberly-Clark, CSFB Private Equity and New England Capital Partners.

May

2009

Clovis Oncology, Inc.: Series A $145M

Posted in I - Series A, Q - 2Q09, R - ROCKY MOUNTAIN, X - Oncology, XX - CO

Clovis Oncology (Boulder, CO) an entity focused on licensing or acquiring rights to oncology compounds in all stages of clinical development, closed a $145M Series A financing. Participants include Domain Associates, New Enterprise Associates, Versant Ventures, Aberdare Ventures, Abingworth, Frazier Healthcare Ventures, and ProQuest Investments.

Apr

2009

OPX Biotechnologies, Inc.: Series B $17.5M

Posted in I - Series B, Q - 2Q09, R - ROCKY MOUNTAIN, X - Biofuel, X - Metabolism, XX - CO

OPX Biotechnologies (Boulder, CO) a research-stage biofuels company using synthetic biology to engineer the microbes as a renewable fuel source, added to their Series B financing bringing the round up to $17.5M. Participants include Braemar Energy Ventures, Altira Group, Mohr Davidow Ventures and X/Seed Capital.

Apr

2009

CeraPedics, Inc.: Series B $15M

Posted in I - Series B, Q - 2Q09, R - ROCKY MOUNTAIN, X - Bone Graft, XX - CO

CeraPedics (Broomfield, CO) a clinical stage device company focused on osteobiologic products for bony voids, closed a $15M Series B financing. Participants include NGN Capital and OrbiMed Advisors.

Mar

2009

BiOptix Diagnostics, Inc.: Series A $3M

Posted in I - Series A, Q - 1Q09, R - ROCKY MOUNTAIN, X - Device (Diagnostic), XX - CO

BiOptix (Boulder, CO) a commercial focused developer of an array-based biomolecule detection system that addresses many markets that currently cannot obtain the needed sensitivity and throughput in a single solution, closed a $3M Series A finacing. Participants include Boulder Ventures.

Feb

2009

OPX Biotechnologies, Inc.: Series B $12.1M

Posted in I - Series C, Q - 1Q09, R - ROCKY MOUNTAIN, X - Bioagriculture, X - Biofuel, XX - CO

OPX Biotechnologies (Boulder, CO) a research-stage biofuels company using synthetic biology to engineer the microbes as a renewable fuel source closed a $12.1M Series B financing. Participants include Braemar Energy Ventures, Mohr Davidow Ventures and X/Seed Capital.

Jan

2009

MD-IT, Inc.: Series B $11M

Posted in I - Series B, Q - 1Q09, R - ROCKY MOUNTAIN, X - TeleMedicine, XX - CO

MD-IT (Boulder, CO) pprovider of medical documentation services and software for physician offices and ambulatory clinics, closed a $11M Series B financing. Participants include J. Burke Capital Partners.

to top of page...